Table 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx Por Satoko Watanabe (59124)

Assuntos:

Table 3_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx Por Satoko Watanabe (59124)

Assuntos:

Table 4_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx Por Satoko Watanabe (59124)

Assuntos:

Data Sheet 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.pdf Por Satoko Watanabe (59124)

Assuntos:

Table 2_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx Por Satoko Watanabe (59124)

Assuntos:

Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx Por Mengying Qian (2541466)

Assuntos:

Enhancing dose selection in phase I cancer trials: Extending the Bayesian Logistic Regression Model with non-DLT adverse events integration Por Andrea Nizzardo (18316247)

Assuntos:

Association of a COVID-19 diagnosis with adverse events, cohort design, follow-up starting on the day after time 0. Por Shelby S. Fisher (22676406)

Assuntos:

Association of a COVID-19 diagnosis with adverse events, SCRI design, marketscan and medicare, follow-up starting on the day after time 0. Por Shelby S. Fisher (22676406)

Assuntos:

Eligibility assessment, covariate assessment, and follow-up windows relative to time 0 for the cohort design. Por Shelby S. Fisher (22676406)

Assuntos:

Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. Por Shelby S. Fisher (22676406)

Assuntos:

Characteristics of included individuals for SCRI and cohort analyses. Por Shelby S. Fisher (22676406)

Assuntos:

Analysis set for each outcome and definition. Por Shelby S. Fisher (22676406)

Assuntos:

Eligibility Assessment, Covariate Assessment, Risk Windows, and Reference Windows Relative to Time 0 for the Self-Controlled Risk Interval Design. Por Shelby S. Fisher (22676406)

Assuntos:

Signal strength of ADE at the drug level ranked by reports. Por Jun Hua Lai (22676523)

Assuntos:

Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS). Por Jun Hua Lai (22676523)

Assuntos:

Time-to-onset analysis using the Weibull distribution test. Por Jun Hua Lai (22676523)

Assuntos:

Characteristics of AEs reports. Por Jun Hua Lai (22676523)

Assuntos:

Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS). Por Jun Hua Lai (22676523)

Assuntos:

Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS). Por Jun Hua Lai (22676523)

Assuntos: